- PRP is a pancreatic proenzyme formulation.
- Study conducted in collaboration with Universities of Jaén and Granada, led by Dr. Maria Belén Toledo.
- PRP monotherapy reduced proliferation by 50% in wild-type and 54% in chemoresistant cells.
- PRP suppressed clonogenic survival by 59% in WT and 39% in GR cells.
- PRP limited wound closure to 21% in WT and 57% in GR cells (controls 100%).
- PRP reduced invasion by 81% in WT and 47% in GR cells.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card